Eldred Rock Partners LLC Sells 18,861 Shares of Novo Nordisk A/S $NVO

Eldred Rock Partners LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 10.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 165,290 shares of the company’s stock after selling 18,861 shares during the period. Novo Nordisk A/S accounts for about 2.2% of Eldred Rock Partners LLC’s investment portfolio, making the stock its 28th biggest holding. Eldred Rock Partners LLC’s holdings in Novo Nordisk A/S were worth $8,410,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of NVO. Capital International Investors raised its holdings in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares in the last quarter. Folketrygdfondet boosted its stake in shares of Novo Nordisk A/S by 1.2% during the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after acquiring an additional 117,370 shares in the last quarter. State Street Corp increased its holdings in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. State Street Corp now owns 6,106,836 shares of the company’s stock valued at $340,125,000 after acquiring an additional 59,153 shares during the last quarter. Finally, Boston Partners bought a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $310,199,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.K. drug regulator NICE recommended Wegovy for heart‑disease prevention, expanding NHS access by about 1.2 million people — a material commercial win that supports longer‑term demand for Wegovy. Novo Nordisk shares rise after Wegovy recommended by Britain’s drug price regulator
• Positive Sentiment: Management launched a Wegovy subscription pricing model and expanded telehealth partnerships to lower out‑of‑pocket costs and improve adherence — a tactical move to protect market share and pricing power in self‑pay segments. NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
• Positive Sentiment: Novo released a cross‑trial comparison (ORION) showing oral Wegovy produced greater mean weight loss and fewer dropouts versus Lilly’s pill — messaging aimed at bluntly defending the oral franchise as Lilly begins commercialization. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Pipeline progress continues: Novo is advancing next‑generation metabolic candidates (including a triple‑agonist program) through early clinical trials, which supports longer‑term upside beyond current GLP‑1 competition. Novo Nordisk Triple Agonist Progress Spurs Questions On Valuation Gap
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — signaling analysts see limited near‑term upside while acknowledging the Wegovy pill momentum. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market coverage notes the shares edged higher and held up early despite Lilly’s approval — suggesting investors had partially priced in competitive pressure. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: FDA approval of Eli Lilly’s oral GLP‑1 (Foundayo/orforglipron) and an expected multi‑billion dollar commercial debut create direct pricing and market‑share pressure on Novo’s Wegovy/Ozempic franchises. Analysts and traders are pricing a more contested oral market going forward. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Broader policy/regulatory risk: reports the administration is considering tariffs of up to 100% on branded drug imports could create volatility and uncertainty for multinational drugmakers if no concessions/deals are struck. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Analyst commentary highlights intensifying duopoly dynamics with Eli Lilly, product gaps in injectables vs. Lilly, and patent/competitive lifecycle concerns — risks that could pressure growth and valuation if market share slips. Novo Nordisk: Competing In A Duopoly

Analysts Set New Price Targets

A number of brokerages have issued reports on NVO. TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research report on Tuesday, March 10th. Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, March 18th. They issued an “outperform” rating and a $175.00 price target on the stock. CICC Research began coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They issued an “outperform” rating and a $73.50 price objective for the company. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Finally, Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Four equities research analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Stock Performance

NVO opened at $36.92 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. The stock’s 50 day moving average price is $43.93 and its two-hundred day moving average price is $49.98. The firm has a market capitalization of $164.86 billion, a P/E ratio of 10.64, a price-to-earnings-growth ratio of 8.63 and a beta of 0.73. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.90 by $0.11. The company had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S’s dividend payout ratio is 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.